Please login to the form below

Not currently logged in
Email:
Password:

SCCHN

This page shows the latest SCCHN news and features for those working in and with pharma, biotech and healthcare.

Bad news for Innate Pharma as BMS-backed drug stumbles

Bad news for Innate Pharma as BMS-backed drug stumbles

Lirilumab combination fails to show additional benefit in SCCHN patients. French biotech Innate Pharma says it can’t see a development path forward for its lead cancer drug lirilumab after another ... additional benefit compared to Opdivo alone in

Latest news

More from news
Approximately 6 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Helen Parfitt joins Research Partnership Helen Parfitt joins Research Partnership

    She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics